X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
aged (12) 12
female (12) 12
index medicus (12) 12
male (12) 12
middle aged (12) 12
cancer (11) 11
chemotherapy (8) 8
adult (7) 7
aged, 80 and over (7) 7
cancer therapies (6) 6
metastasis (6) 6
oncology (6) 6
treatment outcome (6) 6
adenocarcinoma - drug therapy (5) 5
care and treatment (5) 5
clinical trials (5) 5
esophageal cancer (5) 5
stomach neoplasms - drug therapy (5) 5
adenocarcinoma (4) 4
adenocarcinoma - mortality (4) 4
analysis (4) 4
disease-free survival (4) 4
esophageal neoplasms - drug therapy (4) 4
esophageal neoplasms - pathology (4) 4
esophagus (4) 4
follow-up studies (4) 4
gastroenterology & hepatology (4) 4
gastroenterology and hepatology (4) 4
hematology, oncology and palliative medicine (4) 4
iii trial (4) 4
neoplasm staging (4) 4
retrospective studies (4) 4
stomach cancer (4) 4
stomach neoplasms - pathology (4) 4
supportive care (4) 4
survival rate (4) 4
1st-line therapy (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
apoptosis (3) 3
carcinoma, squamous cell - pathology (3) 3
cisplatin - administration & dosage (3) 3
esophageal neoplasms - mortality (3) 3
kaplan-meier estimate (3) 3
medical colleges (3) 3
oncology, experimental (3) 3
proportional hazards models (3) 3
research (3) 3
stomach neoplasms - mortality (3) 3
time factors (3) 3
2nd-line chemotherapy (2) 2
abridged index medicus (2) 2
adenocarcinoma - pathology (2) 2
adenocarcinoma - secondary (2) 2
advanced esophagogastric cancer (2) 2
alcohol (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
breast cancer (2) 2
carcinoma (2) 2
carcinoma, squamous cell - drug therapy (2) 2
cell death (2) 2
diagnosis (2) 2
docetaxel (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
endoscopy (2) 2
esophageal squamous cell carcinoma (2) 2
esophagogastric junction (2) 2
esophagogastric junction - pathology (2) 2
financial disclosure (2) 2
fluorouracil (2) 2
fluorouracil - administration & dosage (2) 2
gene amplification (2) 2
growth (2) 2
growth factors (2) 2
head (2) 2
her2 (2) 2
infusions, intravenous (2) 2
ligands (2) 2
medical research (2) 2
medicine, experimental (2) 2
medicine, general & internal (2) 2
methods (2) 2
mortality (2) 2
paclitaxel (2) 2
paclitaxel - adverse effects (2) 2
pharyngeal neoplasms - pathology (2) 2
platinum (2) 2
postoperative complications (2) 2
product development (2) 2
prognosis (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 631 - 639
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9742, pp. 687 - 697
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1224 - 1235
Summary Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | ONCOLOGY | BEVACIZUMAB | CLINICAL-TRIALS | GROWTH | 2ND-LINE CHEMOTHERAPY | OPEN-LABEL | 1ST-LINE THERAPY | COMBINATION | CANCER | III TRIAL | Confidence Intervals | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Esophageal Neoplasms - mortality | Adult | Female | Remission Induction - methods | Paclitaxel - administration & dosage | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Paclitaxel - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Hospitals | Clinical trials | Monoclonal antibodies | Product development | Antineoplastic agents | Vascular endothelial growth factor | Esophageal cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 11, pp. 1063 - 1069
Summary Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but promising findings have been reported with irinotecan plus... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | 5-FLUOROURACIL | ONCOLOGY | HIGH-DOSE METHOTREXATE | DOXORUBICIN | ADVANCED ESOPHAGOGASTRIC CANCER | COOPERATIVE GROUP | EUROPEAN-ORGANIZATION | 1ST-LINE THERAPY | III TRIAL | CHEMOTHERAPY | Japan - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - secondary | Cisplatin - administration & dosage | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Time Factors | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Administration, Oral | Tegafur - adverse effects | Tegafur - therapeutic use | Proportional Hazards Models | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Oxonic Acid - adverse effects | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Infusions, Intravenous | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Information services | Research | Metastasis | Stomach cancer | Information services industry | Cancer | Fluorouracil | Index Medicus
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 1, pp. 42 - 50
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article